drugset / Trial / NCT00328380
Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.
RandomizedParallel-groupDouble-blindPrevention
Summary
The primary objective of this study is to assess the safety and tolerability of rifaximin 600 mg (3 x 200-mg tablets) once daily compared with placebo when taken for 14 days by healthy subjects to prevent travelers' diarrhea (TD) from all causes.
Timeline
- Start
- 2005-12
- Primary completion
- 2006-12
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rifaximin | Other / unclassified | 600 mg | — |